Why the study?
Does nifedipine reduce post-infarction morbidity and mortality in survivors of acute myocardial infarction?
Does nifedipine reduce post-infarction morbidity and mortality in survivors of acute myocardial infarction?
Routine administration of nifedipine 30 mg/day in survivors of acute myocardial infarction does not reduce mortality or recurrent myocardial infarction.
Answers are grounded in this paper and cite their sources.
Nifedipine confers no post-MI mortality or reinfarction benefit; confirms no role for routine use in survivors.
The efficacy of nifedipine in the prevention of post-infarction morbidity and mortality was evaluated in a double-blind clinical trial of 2276 survivors of acute myocardial infarction recruited from the cardiac departments of 14 Israeli hospitals. The patients were randomized to either nifedipine 30 mg day−1 or placebo between 7 and 21 days after their hospitalization for the acute event. Baseline characteristics of patients in each group were virtually identical for most pertinent variables. Mortality during an average 10-month follow-up period was 5.7% in the placebo group and 5.8% among those receiving nifedipine. Nonfatal recurrent myocardial infarction occurred in 4.8% and 4.4% of placebo and nifedipine patients, respectively. Administration of nifedipine according to the protocol used in the present study had no effect on cardiac events in survivors of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
A 1988 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: